The Pharmaceutical Market: Austria

Publisher Name :
Date:25-Apr-2013
No. of pages:

The macroenvironment for the Austrian pharmaceutical industry is positive. Economic recovery is strengthening, with modest GDP real growth projected in 2012 and 2013. However, the EIU projects that Austria will be affected by the expected euro zone recession. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. Healthcare expenditure has continued its steady growth in recent years. The principal challenge facing the Austrian healthcare system is rising costs. The main reason for this is an ageing population and the uptake of new, more expensive pharmaceuticals.

Cardiovascular drugs are leaders in the Austrian pharmaceutical market, both in terms of value and volume. Other leading therapeutic areas in terms of value are the nervous system, antineoplastic & immunomodulating agents and alimentary tract & metabolism. In terms of volume, other leading therapeutic areas are the alimentary tract & metabolism, the nervous system and the musculoskeletal system. Meanwhile, the leading OTC product group is cough & cold remedies, followed by vitamins & minerals, pain relievers and stomach & digestion products.

Several multinational pharmaceutical companies have production sites in Austria, including Baxter, Boehringer Ingelheim, Fresenius Kabi, Nycomed and Sandoz. Aside from these, there are also a number of small- and medium-sized pharmaceutical companies, as well as several research-based companies.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Austria

Table Of Contents
N/A

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global Biosimilars Market to Grow at a CAGR of 8.3%, to reach $262 billion by 2019
  • Lucrative Biosimilars Space to Erode Biologics Market from 2019, says GlobalData The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking …

  • Saudi Pharmaceutical Market worth $5.9 billion by 2020
  • A high burden of chronic diseases, improving regulatory guidelines and the launch of new products will provide the necessary impetus for the growth of the pharmaceutical market in Saudi Arabia The Saudi pharmaceutical market is one of the largest markets …

  • Puerto Rico Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 99
    BMI View: The pharmaceutical manufacturing industry will continue to be an economic mainstay for Puerto Rico. However, the country is gradually losing attractiveness as a global pharmaceutical production hub, despite the diversification to the generic and biologic drug production. Headline Expenditure Projections ? Pharmaceuticals: USD3.02bn in 2013 to USD3.02bn in 2014; +0.2% in local currency terms. Forecast is below the previous quarter's projection due to new historical numbers. ? Healthcare......
  • Cote d’Ivoire Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 59
    BMI View: Despite our more positive outlook for economic and pharmaceutical growth in Cote d'Ivoire over the long term, the country remains one of the least attractive to multinationals looking to launch innovative products in Africa. This is due to risks in its pharmaceutical environment, including poor patent respect, lack of policy enforcement and approvals expediency and a weak business setting. The healthcare market remains underdeveloped, while the burden of communicable diseases is consid......
  • Myanmar Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 57
    BMI View: The considerable increase in government health expenditure in 2012 highlights Myanmar's commitment to improving healthcare. However, there are several barriers to the improvement of medical services, such as limited funding for healthcare, a lack of basic resources and political instability, which could negatively affect Myanmar's economy. Headline Expenditure Projections ? Pharmaceutical imports: MMK324.8bn (US$350mn) in 2013 to MMK387.5bn (US$390mn) in 2014; +19.3% in local currency ......
  • Poland Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: Polish pharmacies reported flat year-on-year growth in Q114 sales data. However, BMI expect growth to pick up in the remaining quarters of the year as the country's exports increase and household consumption rises. We highlight consumer healthcare products, especially over-the-counter medicines, as a particularly attractive growth area. Poland's lack of exposure to Russia and the regional tension reinforces our view that the country is one of the most attractive markets in Central and ......
  • Kenya Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 105
    BMI View: The growing Kenyan population will support the growth of the country's pharmaceuticals and healthcare industry. While fertility rates have dropped over the last decade, from 5.0 births per woman in 2003 to 4.4 births per woman in 2013, we note that these figures are well above developed state fertility rates. In 2009, the EU-27 average stood at 1.59 live births per woman. However, we note that the country's young population will act as a limiting factor for pharmaceutical demand, prese......
  • Germany Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 134
    BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the average of or below the lowest of the European reference country basket. Additionally, legislators have voted to continue the 2010 implemented price freeze on reimbursed drugs until the end of 2017. However, the long term and clear nature of the measures implemented by the government is a much more......
  • Canada Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 122
    BMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to pharmaceutical companies over the next few years as economic growth in the country gradually accelerates. The hospitable business environment, improving healthcare coverage and broader drug reimbursement lists will continue to provide revenue-generating opportunities for drugmakers. Headline Expenditure Projections ? Pharmaceuticals: CAD25.6bn (USD24.9bn) in 2013 to CAD25.9bn (USD22.5bn) in 2014; +......
  • Turkey Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 125
    BMI View: Data released by the Turkish drugmakers association for 2013 sales corresponds with our own forecasts. We have also modified our pharmaceutical sales forecast for 2014 and beyond to reflect the volatile exchange rate situation. We now see Turkey's lustre as an emerging pharmaceutical market regressing over the medium term. We believe that the business environment will continue to impede the industry and see very little scope for the central government to enact business-friendly reform ......
  • Cameroon Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Mobile health has strong growth potential in Cameroon, given the lack of health infrastructure and medical professionals. The use of mobile health will help to improve accessibility to healthcare, to some extent. However, we maintain that in order for Cameroon to reach its full potential, there needs to be much greater commitment to invest in healthcare services. Headline Expenditure Projections ? Pharmaceuticals: XAF148.82bn (USD300mn) in 2013 to XAF166.95bn (USD320mn) in 2014; +12.2%......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs